Prime Medicine, Inc. has announced a significant public offering of its common stock, aiming to raise approximately $134.7 million. The offering includes 35,714,286 shares priced at $3.50 each, with an option for underwriters to purchase an additional 5,357,142 shares. This strategic move is expected to bolster the company's financial position and support its ongoing research and development efforts.
The offering is being managed by Jefferies LLC, TD Securities (USA) LLC, and Goldman Sachs & Co. LLC, who are acting as representatives of the underwriters. The expected closing date for the offering is November 12, 2026, subject to customary closing conditions.
Background
Prime Medicine, Inc. is a biotechnology company focused on developing innovative therapies for genetic diseases. The company is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). Prime Medicine trades on the Nasdaq under the ticker symbol PRME.
What the Filing Says
According to the recent SEC filing, "On November 10, 2026, Prime Medicine, Inc. entered into an Underwriting Agreement... related to an underwritten public offering of 35,714,286 shares of the Company’s common stock, par value $0.00001 per share, at a public offering price of $3.50 per share." The filing also states that the company plans to use the net proceeds primarily to support its Wilson disease and alpha-1 antitrypsin deficiency programs.
Impact
This public offering may affect various stakeholders, including investors, employees, and the broader biotechnology industry. By raising substantial funds, Prime Medicine aims to enhance its research capabilities and accelerate the development of its therapeutic programs.
What's Next
The offering is expected to close on or about November 12, 2026, pending the satisfaction of customary closing conditions. Further details regarding the use of proceeds and the impact on ongoing projects may be disclosed in future filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










